CZC 19945 | 1159822-52-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: CZC 19945
• 英文别名: 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-pyridine-3-sulfonic acid tert-butylamide；5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-tert-butylpyridine-3-sulfonamide
• CAS: 1159822-52-2
• 化学式: C₁₅H₁₈N₆O₂S
• 分子量: 346.413
• InChiKey: YKJGGEMOMSRCDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  124
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  CZC 19945 在 吡啶 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 1-[6-[5-(Tert-butylsulfamoyl)pyridin-3-yl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-3-(2-pyrazin-2-ylethyl)urea
  参考文献：
  名称：

  Discovery of novel PI3Kγ/δ inhibitors as potential agents for inflammation

  摘要：

  Dual PI3K gamma/delta inhibitors have recently been shown to be suitable targets for inflammatory and respiratory diseases. In a recent study we described the discovery of selective PI3K gamma inhibitors based on a triazolopyridine scaffold. Herein, we describe the elaboration of this structural class into dual PI3K gamma/delta inhibitors with excellent selectivity over the other PI3K isoforms and the general kinome. Structural optimization led to the identification of two derivatives which showed significant efficacy in an acute model of lung inflammation. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.121
• 作为产物：
  描述：

  N-tert-butyl-6'-(3-(ethoxycarbonyl)thioureido)-3,3'-bipyridine-5-sulfonamide 在 盐酸羟胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 18.0h， 生成 CZC 19945
  参考文献：
  名称：

  Discovery of novel PI3Kγ/δ inhibitors as potential agents for inflammation

  摘要：

  Dual PI3K gamma/delta inhibitors have recently been shown to be suitable targets for inflammatory and respiratory diseases. In a recent study we described the discovery of selective PI3K gamma inhibitors based on a triazolopyridine scaffold. Herein, we describe the elaboration of this structural class into dual PI3K gamma/delta inhibitors with excellent selectivity over the other PI3K isoforms and the general kinome. Structural optimization led to the identification of two derivatives which showed significant efficacy in an acute model of lung inflammation. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.121

文献信息

• [EN] METHODS FOR THE IDENTIFICATION OF PHOSPHATIDYLINOSITOL KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF PHOSPHATIDYLINOSITOL KINASE PROTEINS<br/>[FR] PROCÉDÉS PERMETTANT L'IDENTIFICATION DE MOLÉCULES INTERAGISSANT AVEC LES PHOSPHATIDYLINOSITOL KINASES, ET LA PURIFICATION DE PROTÉINES PHOSPHATIDYLINOSITOL KINASES
  申请人：CELLZOME AG

  公开号：WO2010133318A1

  公开（公告）日：2010-11-25

  The present invention relates to immobilization compounds of formula (I), immobilization products and preparations thereof as well as methods and uses for the identification of phosphatidylinositol kinase interacting compounds or for the purification or identification of phosphatidylinositol kinase proteins.

  本发明涉及公式（I）的固定化合物，固定化产物及其制备方法，以及用于识别磷脂酰肌醇激酶相互作用化合物或用于纯化或鉴定磷脂酰肌醇激酶蛋白的方法和用途。
• [EN] 7-PYRIDINYL- OR PHENYL- SUBSTITUTED TRIAZOLO [1, 5 -A] PYRIDINES AS PI3K INHIBITORS<br/>[FR] TRIAZOLO[1,5-A]PYRIDINES 7-PYRIDINYLE- OU PHÉNYL-SUBSTITUÉES COMME INHIBITEURS DE PI3K
  申请人：CELLZOME LTD

  公开号：WO2010057877A1

  公开（公告）日：2010-05-27

  The invention relates to compounds of formula (I), wherein X, X1, R and R1 to R4 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of PI3K, for the treatment or prophylaxis of immunological, inflammatory, autoimmune, or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.

  该发明涉及具有以下式（I）的化合物，其中X、X1、R和R1至R4的含义如描述和权利要求中所述。所述化合物可用作蛋白激酶抑制剂，特别是PI3K的抑制剂，用于治疗或预防免疫、炎症、自身免疫或过敏性疾病。该发明还涉及包括所述化合物的药物组合物，以及制备此类化合物以及作为药物的生产和使用。
• METHODS FOR THE IDENTIFICATION OF PHOSPHATIDYLINOSITOL KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF PHOSPHATIDYLINOSITOL KINASE PROTEINS
  申请人：Bell Kathryn

  公开号：US20120135421A1

  公开（公告）日：2012-05-31

  The present invention relates to immobilization compounds of formula (I), immobilization products and preparations thereof as well as methods and uses for the identification of phosphatidylinositol kinase interacting compounds or for the purification or identification of phosphatidylinositol kinase proteins.

  本发明涉及公式（I）的固定化化合物、固定化产物及其制备方法和用途，以及用于鉴定磷脂酰肌醇激酶相互作用化合物或用于纯化或鉴定磷脂酰肌醇激酶蛋白的方法和用途。
• Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins
  申请人：Bell Kathryn

  公开号：US08367830B2

  公开（公告）日：2013-02-05

  The present invention relates to immobilization compounds of formula (I), immobilization products and preparations thereof as well as methods and uses for the identification of phosphatidylinositol kinase interacting compounds or for the purification or identification of phosphatidylinositol kinase proteins.

  本发明涉及公式（I）的固定化化合物，固定化产物及其制备方法和用途，以及用于鉴定磷脂酰肌醇激酶相互作用化合物或用于纯化或鉴定磷脂酰肌醇激酶蛋白质的方法和用途。
• AMINO TRIAZOLES AS PI3K INHIBITORS
  申请人：Ramsden Nigel

  公开号：US20110021497A1

  公开（公告）日：2011-01-27

  The invention relates to compounds of formula (I) wherein X, T 1 and R 1 to R 3 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of PI3K, for the treatment or prophylaxis of immunological, inflammatory, autoimmune, or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.

  本发明涉及式(I)的化合物，其中X、T1和R1至R3具有所述说明书和权利要求中所述的含义。所述化合物可用作蛋白激酶抑制剂，特别是PI3K的抑制剂，用于治疗或预防免疫、炎症、自身免疫或过敏性疾病。本发明还涉及包括所述化合物的制药组合物，以及制备此类化合物以及作为药物的生产和使用。